Louis C. Bock

Cellective Therapeutics, Inc. provides biopharmaceuticals products. It develops monoclonal antibodies for the treatment of oncology and autoimmune diseases. Cellective Therapeutics products include monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22 are in preclinical stage programs. It was founded by Thomas F. Tedder and Alter E. Geller in May, 2003 and is headquartered in Durham, NC

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Sonexa Therapeutics, Inc. developed drug treatments for Alzheimer's disease (AD) and related disorders. Its lead compound, ST101 had demonstrated both the cognitive benefits of currently marketed AD treatments along with significant disease modifying effects. The company was founded in January 2008 and was headquartered in San Diego, CA.

Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA.

VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA.

Prestwick Pharmaceuticals, Inc. develops drugs for diseases related to the central nervous system. Its drugs are used in curing diseases such as Huntington's, Parkinson's, restless legs syndrome, schizophrenia, autism, Alzheimer's, and sleep apnea diseases. The company was founded in 2002 and is headquartered in Washington DC.

Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA.

New Century Hospice, Inc. provides hospice care services. It offers physician directed nursing care, medical, social & spiritual counselling, bereavement, trained volunteers, related medications, medical equipment and supplies, physical, speech, and other related therapies, continuous care for acute symptom management and short-term inpatient care. The company was founded by David Charles Gasmire in 2006 and is headquartered in Moorsville, NC.

PowerVision, Inc. develops fluid-controlled intraocular lens. The firm provides FluidVision accommodating intraocular lens technology, which restores the vision of youth to middle aged or elderly individuals affected by presbyopia and cataracts regain to adjust focus for clear vision at all distances. The company was founded by Matthew A. Frinzi, Randy McDonald, and Barry Cheskin in 2002 and is headquartered in Belmont, CA.

Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX.

CardioKinetix, Inc. develops ventricular partitioning device for heart failure disease. It develops transcatheter implant called the Parachute Ventricular Partitioning Device, which intends to treat heart failure resulting from a heart attack in patients by improving overall cardiac function. The company was founded by Alexander Khairkhahan, Serjan D. Nikolic and Hugh R. Sharkey in 2002 and is headquartered in Menlo Park, CA.

SHVMS, LLC (Sante Ventures) is a Venture Capital firm founded in 2006 by Joe Hal Cunningham, Kevin Myles Lalande and Doug Dewitt French. The firm is headquartered in Austin, Texas.

Archer Venture Management, Inc. provides investment advice. The private company is based in Los Angeles, CA.

Iterion Therapeutics, Inc. provides pharmaceuticals services. The firm products are used in the treatment of colorectal, hematopoietic, and other targeted cancers. The company was founded by Jonathan P. Northrup in 2010 and is headquartered in Houston, TX.

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.